novo nordisk fda semaglutide asks to prevent compounders from making GLP-1 knockoffs Millions are trying FDA-authorized alternatives

Cell Metab (2018) 28(2):1834

Ozempic Drug same as Wegovy, but usually intended for diabetes

The peptide binds to GLP-1 receptors throughout the body, triggering a cascade of metabolic effects that include increased insulin secretion, decreased glucagon release, delayed gastric emptying, and reduced appetite signaling in the hypothalamus

Quick Answer: GLP-1 receptor agonists are associated with a modest but statistically significant increase in gallbladder disease risk, including gallstones and cholecystitis, affecting approximately 13% of users

Employers should stay informed about these regulatory changes to manage prescription drug costs and ensure employee medication access